Harbour BioMed has reported results from a Phase Ib clinical trial of porustobart (HBM4003) combined with toripalimab for the treatment of hepatocellular carcinoma (HCC).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,